Luc Friboulet
Inserm · 583 works · 10,135 citations · h-index 44
Top works
- Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK -Rearranged Lung Cancer
- The ALK Inhibitor Ceritinib Overcomes Crizotinib Resistance in Non–Small Cell Lung Cancer
- Patient-derived models of acquired resistance can identify effective drug combinations for cancer
- Acquired Resistance to Crizotinib from a Mutation in CD74 – ROS1
- PF-06463922, an ALK/ROS1 Inhibitor, Overcomes Resistance to First and Second Generation ALK Inhibitors in Preclinical Models
- Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F
- Two Novel ALK Mutations Mediate Acquired Resistance to the Next-Generation ALK Inhibitor Alectinib
- ERCC1 Isoform Expression and DNA Repair in Non–Small-Cell Lung Cancer
- 80P Tumor microenvironment (TME) defines prognosis of EGFR-mutant non-small cell lung cancer (NSCLC)
- Cabozantinib Overcomes Crizotinib Resistance in ROS1 Fusion–Positive Cancer
- Patterns of Metastatic Spread and Mechanisms of Resistance to Crizotinib in ROS1-Positive Non–Small-Cell Lung Cancer
- Sequential ALK Inhibitors Can Select for Lorlatinib-Resistant Compound ALK Mutations in ALK-Positive Lung Cancer
- Progression-Free and Overall Survival in ALK-Positive NSCLC Patients Treated with Sequential Crizotinib and Ceritinib
- Making the first move in EGFR-driven or ALK-driven NSCLC: first-generation or next-generation TKI?
- Molecular mechanisms of resistance to first- and second-generation ALK inhibitors in ALK-rearranged lung cancer
- Crizotinib-Resistant ROS1 Mutations Reveal a Predictive Kinase Inhibitor Sensitivity Model for ROS1 - and ALK -Rearranged Lung Cancers
- Clinicogenomic Analysis of FGFR2 -Rearranged Cholangiocarcinoma Identifies Correlates of Response and Mechanisms of Resistance to Pemigatinib
- P-glycoprotein Mediates Ceritinib Resistance in Anaplastic Lymphoma Kinase-rearranged Non-small Cell Lung Cancer
- Secreted PD-L1 variants mediate resistance to PD-L1 blockade therapy in non–small cell lung cancer
- Primary Patient-Derived Cancer Cells and Their Potential for Personalized Cancer Patient Care